Outcomes of adult urogenital sarcomas: Analysis of surveillance, epidemiology, and end results (SEER) database 2004 to 2015.

Authors

null

Snigdha Nutalapati

University of Kentucky, Lexington, KY

Snigdha Nutalapati , Quan Chen , Bin Huang , Reema Anil Patel , Mehmet Asim Bilen , Zin Myint

Organizations

University of Kentucky, Lexington, KY, Kentucky Cancer Registry, Lexington, KY, Markey Cancer Center, Lexington, KY, Department of Hematology and Medical Oncology, Emory University School of Medicine, Atlanta, GA

Research Funding

No funding received
None.

Background: Urogenital sarcomas are rare type of soft tissue sarcomas and represent only 1-2% of all genitourinary cancers. Given the paucity of literature, we aimed to study the clinical characteristics and factors impact outcomes of adult urological sarcomas. Methods: Adult males aged ≥ 20 years with sarcomas primarily originating from urogenital sites were identified from national SEER database between 2004-2015. Descriptive analysis was performed for all cases. Survival analysis, including Kaplan Meier estimates and Cox regression were performed. Results: A total of 1177 genitourinary sarcomas were identified. Urinary bladder (20.56%) was the most common primary site followed by spermatic cord (20.31%) and kidney (17.33%). The most common histological subtype was liposarcoma (32.9%) followed by leiomyosarcoma (32.0%). 10-year survival rate was highest for liposarcoma 58.3% (95% CI 50.3-65.5) followed by leiomyosarcoma 40.2% (95% CI 32.0-48.2), rhabdomyosarcoma 37.3% (95% CI 22.6-52.1), synovial sarcoma 22.7% (95% CI 5.6-46.6), carcinosarcoma 8.9% (95% CI 4.3-15.4) and 0% for angiosarcoma. Median follow up was 23 months and overall median survival was 54 months. There was a significant overall survival difference by age, race, primary sites, histological subtypes, grade, stage, insurance status, geographic, socioeconomic status and treatment in both univariate and multivariate analysis. On multivariate analysis, factors associated with unfavorable prognosis include age > 75 years (HR 3.9, 95% CI 2.9-5.2), distant metastasis (HR 2.0, 95% CI 1.5-2.7), ureteral sarcomas (HR 6.2, 95% CI 2.3-17.1) and having Medicaid insurance (HR 1.7, 95% CI 1.2-2.3).Surgery alone (HR 0.5, 95% CI 0.4-0.7) or in combination with chemotherapy (HR 0.4, 95% CI 0.3-0.6) or radiation (HR 0.4, 95% CI 0.3-0.6) had favorable prognosis compared to non-surgical approach. Conclusions: Urinary bladder is the most common primary sites of all urological sarcomas. Our study showed age > 75, poorly differentiated histology, angiosarcoma subtype, ureteral primary site, distant metastasis, poor socioeconomic status, Appalachian area and radiation alone were associated with less favorable outcomes.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Abstract Details

Meeting

2020 Genitourinary Cancers Symposium

Session Type

Poster Session

Session Title

Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers

Track

Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer

Sub Track

Other

Citation

J Clin Oncol 38, 2020 (suppl 6; abstr 423)

Abstract #

423

Poster Bd #

E22

Abstract Disclosures

Similar Abstracts

First Author: Jaikin Patel

Abstract

2023 ASCO Annual Meeting

Alternative splicing (AS) regulation as a novel therapeutic target in soft-tissue sarcoma (STS).

First Author: David Silva Moura

First Author: Emanuela Palmerini